StemCells still going after Neuralstem
There was the discussion of litigate vs. license:
"While we are disappointed that Neuralstem chose to escalate matters, we have a duty to our shareholders to protect our good name and the significant value of our intellectual property portfolio built over the years," StemCells Chief Executive Officer Martin McGlynn said in a statement. "Litigation of this type can be very time consuming and expensive and might have been avoided had Neuralstem chosen to negotiate a license as others have."
See also
http://ipbiz.blogspot.com/2008/04/battling-press-releases-on-meaning-of.html
0 Comments:
Post a Comment
<< Home